Filtered By:
Cancer: Chronic Lymphocytic Leukemia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 209 results found since Jan 2013.

Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib.
PMID: 29174859 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - November 23, 2017 Category: Allergy & Immunology Authors: Jiang F, Verma P Tags: Ann Allergy Asthma Immunol Source Type: research

Resolution of Eosinophilia and Elevated Immunoglobulin E with Ibrutinib for Chronic Lymphocytic Leukemia.
PMID: 30009879 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - July 12, 2018 Category: Allergy & Immunology Authors: Harada K, Brook JP, Lobo FM Tags: Ann Allergy Asthma Immunol Source Type: research

Hematologic Malignancies Identified in Patients with Hypereosinophilia and Hypereosinophilic Syndromes
Conclusions The development of hematologic malignancies in this referral population with eosinophilia was rare (0.2%), but more common in those with hypereosinophilia (5.1%). Non-Hodgkin's lymphomas, particularly T-cell-derived malignancies, were most commonly diagnosed. Patients with preexisting hypereosinophilia were diagnosed with hematologic conditions that were rarer within the general population.
Source: The Journal of Allergy and Clinical Immunology: In Practice - September 3, 2015 Category: Allergy & Immunology Source Type: research

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.
Abstract Due to the increase in utilization of chemotherapies and antibodies, drug hypersensitivity reactions have increased dramatically worldwide, preventing the use of first-line therapies and impacting patients' survival and quality of life. Some of the more frequently used medications in cancer include taxanes for ovarian, lung, breast, and prostate cancers. Monoclonal antibodies are used in the treatment of neoplastic, autoimmune, and inflammatory diseases, and their clinical applications are becoming broader. Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-α, CD30, VEGF-A, IgE, an...
Source: Clinical Colorectal Cancer - June 7, 2016 Category: Cancer & Oncology Authors: Bonamichi-Santos R, Castells M Tags: Clin Rev Allergy Immunol Source Type: research

Ibrutinib, a Bruton ’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity
Approximately 15 million people, including 8% of children, in the United States have food allergy and are at risk of having life-threatening anaphylactic reactions.1 There is an unmet need for the prevention of such reactions. Tyrosine kinases, including Bruton's tyrosine kinase (BTK), have been shown to be critical for allergen reactivity by transducing Fc εRI crosslinking signals into cellular activation and mediator release from mast cells and basophils.2 Pharmacyclics, Inc, together with Janssen Pharmaceuticals, recently received Food and Drug Administration approval of ibrutinib (Imbruvica, PCI-32765) as a selective,...
Source: Journal of Allergy and Clinical Immunology - April 4, 2017 Category: Allergy & Immunology Authors: Jennifer A. Regan, Yun Cao, Melanie C. Dispenza, Shuo Ma, Leo I. Gordon, Adam M. Petrich, Bruce S. Bochner Tags: Letter to the Editor Source Type: research

M101 the effect of bruton tyrosine kinase inhibitor ibrutinib on diagnostic evaluation amoxicillin allergy
Bruton Tyrosine Kinase (BTK) Inhibitors are used to treat chronic lymphocytic leukemia. BTK is involved in B cell receptor signaling and downstream signaling in mast cell and basophils. The BTK inhibitor Ibrutinib may block mast cell and basophil mediator release and may affect IgE levels.
Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: R. Charya, D. Sheth, A. Aggarwal Source Type: research

CD8+ T-cells Co-expressing PD-1 and TIGIT Are Highly Frequent in Chronic Lymphocytic Leukemia
Iran J Allergy Asthma Immunol. 2021 Dec 8;20(6):751-763. doi: 10.18502/ijaai.v20i6.8027.ABSTRACTThe role of immune checkpoint receptors in T-cell exhaustion has been demonstrated in several cancers. We investigated the co-expression of TIGIT/PD-1 and LAG-3/PD-1 cells in patients with chronic lymphocytic leukemia (CLL). The frequencies of TIGIT+PD-1+CD8+and LAG-3+PD-1+CD8+cells and relative mRNA expression of LSECtin and CD155 were examined in PBMCs from 33 CLL patients and 20 controls. The percentage of TIGIT+PD-1+CD8+cells was significantly higher in CLL patients than in control subjects, with the preference in advanced s...
Source: Iranian Journal of Allergy, Asthma and Immunology - December 18, 2021 Category: Allergy & Immunology Authors: Reza Hajiasghar-Sharbaf Hossein Asgarian-Omran Reza Valadan Hadi Hossein-Nattaj Ramin Shekarriz Ehsan Zaboli Ghasem Janbabaei Mohsen Tehrani Source Type: research